TITLE

Randomized, Double-Blind, Dose-Ranging Study of TAK-875, a Novel GPR40 Agonist, in Japanese Patients With Inadequately Controlled Type 2 Diabetes

AUTHOR(S)
KAKU, KOHEI; ARAKI, TAKAHIRO; YOSHINAKA, RYOJI
PUB. DATE
February 2013
SOURCE
Diabetes Care;Feb2013, Vol. 36 Issue 2, p245
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE--Assessment of the efficacy and safety of TAK-875 (a novel GPR40 agonist) in Japanese patients with type 2 diabetes inadequately controlled by diet/exercise. RESEARCH DESIGN AND METHODS--This was a phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled, 12-week dose-ranging evaluation of TAK-875 (6.25-200mg once daily)with the primary end point of change in A1C at week 12. A nonblinded group received 1 mg glimepiride once daily as an active control. RESULTS--A total of 396 patients were randomized to receive TAK-875 (n = 299), placebo (n = 48), or glimepiride (n = 49). The least square mean changes in A1C at week 12 from baseline were as follows: 0.09% in the placebo group; -0.54, -0.67, -0.88, -1.27, -1.29, and -1.40% in the 6.25-, 12.5-, 25-, 50-, 100-, and 200-mg TAK-875 groups, respectively; and -1.32% in the 1-mg glimepiride group. All TAK-875 groups had statistically significant reductions in A1C compared with placebo (P < 0.0001), and those receiving ≥50 mg TAK-875 achieved reductions in A1C equivalent to those with glimepiride. Results for other glycemic parameters, including improvements during a meal tolerance test, mirrored these positive findings with TAK-875. There were no significant differences in incidence of adverse events among the groups and no dose-dependent changes in tolerability. Hypoglycemic episodeswere reported in 0.7% of patients in the TAK-875 groups and in 4.1% of the glimepiride group. CONCLUSIONSdTAK-875 produced clinically and statistically significant improvements in glycemic control in patients with type 2 diabetes inadequately controlled by diet and exercise, and it was well tolerated with a lower propensity to cause hypoglycemia.
ACCESSION #
85125680

 

Related Articles

  • Effect of camel milk on glycemic control and insulin requirement in patients with type 1 diabetes: 2-years randomized controlled trial. Agrawal, R P; Jain, S; Shah, S; Chopra, A; Agarwal, V // European Journal of Clinical Nutrition;Sep2011, Vol. 65 Issue 9, p1048 

    Background/Objectives:Hypoglycemic effect of camel milk supplementation in experimental rat model and significant reduction in doses of insulin in type 1 diabetic patients have been observed in our previous studies. This long-term study was undertaken to assess the efficacy, safety and...

  • A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Tilden, Dominic P.; Mariz, Segundo; O'Bryan-Tear, Gillies; Bottomley, Julia; Diamantopoulos, Alexander // PharmacoEconomics;2007, Vol. 25 Issue 1, p39 

    Introduction: Adding pioglitazone or rosiglitazone to existing therapy are alternative treatment options for patients with type 2 diabetes mellitus who have insufficient glycaemic control while receiving the maximal tolerated dose of metformin monotherapy. Our objective was to...

  • Antidiabetic Plants of Iran. Shojaii, Asie; Dabaghian, Fataneh Hashem; Goushegir, Ashrafeddin; Fard, Mehri Abdollahi // Acta Medica Iranica;2011, Vol. 49 Issue 10, p637 

    Abstract- To identify the antidiabetic plants of Iran, a systematic review of the published literature on the efficacy of Iranian medicinal plant for glucose control in patients with type 2 diabetes mellitus was conducted. We performed an electronic literature search of MEDLINE, Science Direct,...

  • A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers. Wilding, John P.H.; Norwood, Paul; T'Joen, Caroline; Bastien, Arnaud; List, James F.; Fiedorek, Fred T. // Diabetes Care;Sep2009, Vol. 32 Issue 9, p1656 

    OBJECTIVE -- To determine whether dapagliflozin, which selectively inhibits renal glucose reabsorption, lowers hyperglycemia in patients with type 2 diabetes that is poorly controlled with high insulin doses plus oral antidiabetic agents (OADs). RESEARCH DESIGN AND METHODS -- This was a...

  • The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone. Defronzo, Ralph A.; Hissa, Miguel N.; Garber, Alan J.; Gross, Jorge Luiz; Duan, Raina Yuyan; Ravichandran, Shoba; Chen, Roland S. // Diabetes Care;Sep2009, Vol. 32 Issue 9, p1649 

    OBJECTIVE -- This 24-week trial assessed the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes with inadequate glycemic control with metformin alone. RESEARCH DESIGN AND METHODS -- This was a randomized, double-blind, placebo-controlled study of saxagliptin...

  • The effects of probiotic bacteria on glycaemic control in overweight men and women: a randomised controlled trial. Ivey, K L; Hodgson, J M; Kerr, D A; Lewis, J R; Thompson, P L; Prince, R L // European Journal of Clinical Nutrition;Apr2014, Vol. 68 Issue 4, p447 

    Background/Objectives:Evidence from animal and in vitro models suggest a role of probiotic bacteria in improving glycaemic control and delaying the onset of type 2 diabetes. However, the evidence from controlled trials in humans is limited. The objective was to determine if the probiotic...

  • Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males. Jie Zhu; Min Song; Hong-Yi Tan; Li-Hua Huang; Zhi-Jun Huang; Chang Liu; Zhi-Min Fu; Yuan-Yuan Huang; Zhi-Rong Tan; Xiao-Ping Chen; Hong Yuan; Guo-Ping Yang // Pakistan Journal of Pharmaceutical Sciences;May2013, Vol. 26 Issue 3, p577 

    The effect of pitavastatin and SLCO1B1 genetic background on the pharmacokinetic and pharmacodynamic properties of repaglinide was investigated. In this randomized, placebo-controlled, crossover study, twelve healthy Chinese males were administered with pitavastatin 4 mg/d or the placebo for 5 d...

  • High-Dose Vitamin D Supplementation in People With Prediabetes and Hypovitaminosis D. DAVIDSON, MAYER B.; DURAN, PETRA; LEE, MARTIN L.; FRIEDMAN, THEODORE C. // Diabetes Care;Feb2013, Vol. 36 Issue 2, p260 

    OBJECTIVE--Low vitamin D levels predict the development of diabetes. This double-blind, randomized, control study in subjects with prediabetes and hypovitaminosis D evaluated whether high doses of vitamin D for 1 year affected insulin secretion, insulin sensitivity, and the development of...

  • weight-reducing agents improve glycaemic control and reduce progression to diabetes. Berry, Diane // Evidence Based Nursing;Apr2009, Vol. 12 Issue 2, p8 

    The article focuses on randomised, double-blind placebo controlled trials which examined whether weight-reducing agents could affect glycaemic parameters and risk of type two diabetes in predisposed patients. These trials evaluated drug therapy and reduced-calorie diets. Included in the outcomes...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics